Mobic in Japan: prescription, pharmacy and pricing
Mobic (Meloxicam) is available in Japan under the regulatory framework of PMDA (Pharmaceuticals and Medical Devices Agency). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Mobic 7.5mg, 15mg.
- Regulator
- PMDA (Pharmaceuticals and Medical Devices Agency)
- Currency
- JPY
- Active ingredients
- Meloxicam
- Available dosages
- 7.5mg, 15mg
Prescription status in Japan
Japan classifies medicines into prescription drugs (医療用医薬品) and OTC drugs (一般用医薬品), the latter further divided into pharmacist-only (第1類) and self-service classes. The Ministry of Health, Labour and Welfare (MHLW) sets the regulatory framework; PMDA reviews safety and efficacy. Mobic contains the active ingredient Meloxicam, in the Pain Relief Medications class, and its classification in Japan follows the standard rules of PMDA (Pharmaceuticals and Medical Devices Agency).
Pharmacy dispensing
Japanese pharmacies (薬局) and drugstores (ドラッグストア) such as Matsumoto Kiyoshi and Welcia are widespread. Prescription dispensing pharmacies (調剤薬局) are usually located near hospitals and clinics; pharmacist counselling at dispensing is mandated by the Pharmaceutical Affairs Law. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Mobic at the available strengths (7.5mg, 15mg).
Online and tele-prescribing access
Japan permits online sale of most OTC medicines under the 2014 amendments to the Pharmaceutical Affairs Law, with class-based restrictions. Online prescription dispensing is allowed via licensed pharmacies after a face-to-face or telemedicine consultation; personal importation of prescription medication is restricted to limited quantities for personal use. Buying Mobic from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Meloxicam.
When Mobic is prescribed
Mobic is approved in adults for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Pricing and availability in JPY
Retail pricing in Japan depends on the strength (7.5mg, 15mg), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Mobic in Japan? ▾
Japan classifies medicines into prescription drugs (医療用医薬品) and OTC drugs (一般用医薬品), the latter further divided into pharmacist-only (第1類) and self-service classes. The Ministry of Health, Labour and Welfare (MHLW) sets the regulatory framework; PMDA reviews safety and efficacy. In practice, Mobic follows the status of its active ingredient Meloxicam in the regulatory system of PMDA (Pharmaceuticals and Medical Devices Agency).
Is generic Mobic available in Japan? ▾
Authorised generics of Meloxicam are typically available in Japan at a lower cost than branded Mobic, with bioequivalence required by PMDA (Pharmaceuticals and Medical Devices Agency). Substitution is handled by the pharmacist under local equivalence rules.
How much does Mobic cost in JPY? ▾
Prices in JPY vary by pharmacy and by strength (7.5mg, 15mg). Authorised generics of Meloxicam are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in Japan.
Mobic in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- AustriaBASG (Federal Office for Safety in Health Care)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.